The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease

Research output: Contribution to journalArticlepeer-review


  • Ma Khamashta
  • In Bruce
  • DA Isenberg
  • O Ateka-Barrutia
  • M Gayed
  • C Donatti
  • A-L Guillermin
  • J Foo
  • A Perna

Colleges, School and Institutes

External organisations

  • 1Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK.


ObjectivesThe aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only.MethodsA cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources.ResultsAt baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p 


Original languageEnglish
Publication statusPublished - 19 Dec 2013